Abramson Cancer Center - University of Pennsylvania (UPENN)
University of Pennsylvania
Philadelphia, PA
Not yet accepting
MonumenTAL-8
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Phase 2
Accepting patients
JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
- Trispecific Antibody
- BCMA
- GPRC5D
- Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
LimiTec
Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 2
Accepting patients
Cevostamab after CAR-T Cell Therapy
Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- FCRH5
- Post-CAR T
- Phase 2
Accepting patients
P-BCMA-ALLO1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
- Has results
Accepting patients
Investigational Cord Blood Units
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Cord Blood
- Phase 2
Accepting patients
Belantamab Mafodotin
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- Autologous Stem Cell Transplant
- BCMA
- Maintenance
- Phase 2
- Phase 1/2
- Has results
Not currently accepting
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- BCMA
- Phase 3
1 hidden based on your filters. Show All